Skip Navigation

Cardiovascular Research 2002 53(2):481-486; doi:10.1016/S0008-6363(01)00499-0
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yasuda, S.
Right arrow Articles by Nonogi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yasuda, S.
Right arrow Articles by Nonogi, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2001, European Society of Cardiology

Local delivery of low-dose docetaxel, a novel microtubule polymerizing agent, reduces neointimal hyperplasia in a balloon-injured rabbit iliac artery model

Satoshi Yasudaa,*, Teruo Noguchia, Masahiro Gohdaa, Takashi Araib, Nobumasa Tsutsuib, Yasuhide Nakayamac, Takehisa Matsudac and Hiroshi Nonogia

aNational Cardiovascular Center, Division of Cardiology, Department of Medicine, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan
bTokai Medical Products Inc, Aichi, Japan
cNational Cardiovascular Center Research Institute, Department of Bioengineering, Osaka, Japan

syasuda{at}hsp.ncvc.go.jp

* Corresponding author. Tel.: +81-6-6833-5012; fax: +81-6-6872-7486

Objective: Docetaxel (DOC) is a novel microtubule polymerizing agent, with superior antiproliferative properties as compared to paclitaxel. DOC is therefore a potential therapeutic tool for the prevention of restenosis following angioplasty. However, DOC has systemic toxicity such as leukocytopenia, which occurs in a dose-dependent manner. To minimize such adverse effects, we carried out local delivery of low-dose DOC directly to injured vessel sites. Methods: The rabbit iliac artery was denuded, and then DOC (2 mg) or control vehicle was administered locally 20 min, via a local drug delivery catheter. Results: The levels of DOC in the plasma were within ng/ml range, eliminating hematopoietic side effects. Seven days after the local delivery (DOC: n=4, control: n=4), DOC decreased the number of Ki-67-labeled cells in the intima (DOC: 22±10 vs. control: 66±18 cells/mm2, P<0.01), indicating a decreased proliferative activity. At 28 days (DOC: n=8, control: n=8), computer-assisted morphometric analysis demonstrated that DOC significantly reduced the intimal area (DOC: 0.15±0.13 vs. control: 0.70±0.13 mm2, P<0.01). There was also a decrease in medial area in the DOC-treated vessels (DOC: 0.62±0.17 vs. control: 1.13±0.38 mm2, P<0.01). Conclusions: Local delivery of DOC, even after a single low-dose administration, effectively inhibits neointimal hyperplasia. Such administration is associated with a minimal likelihood of systemic adverse effects (leukocytopenia), but potentially induces local toxicity (a decrease in medial wall thickness) due to extensive cytotoxic effect.

KEYWORDS DOC=Docetaxel; PTCA=Percutaneous Transluminal Coronary Angioplasty; WBC=White Blood Cell; vWF=von Willebrand's factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
M. Sturek and H. K. Reddy
New tools for prevention of restenosis could decrease the 'oculo-stento' reflex
Cardiovasc Res, February 1, 2002; 53(2): 292 - 293.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.